FI3710000T3 - Tradipitantti käytettäväksi gastropareesin hoidossa - Google Patents

Tradipitantti käytettäväksi gastropareesin hoidossa Download PDF

Info

Publication number
FI3710000T3
FI3710000T3 FIEP18821773.1T FI18821773T FI3710000T3 FI 3710000 T3 FI3710000 T3 FI 3710000T3 FI 18821773 T FI18821773 T FI 18821773T FI 3710000 T3 FI3710000 T3 FI 3710000T3
Authority
FI
Finland
Prior art keywords
tradipitant
use according
dose
day
human subject
Prior art date
Application number
FIEP18821773.1T
Other languages
English (en)
Finnish (fi)
Inventor
Mihael Polymeropoulos
Gunther Birznieks
Original Assignee
Vanda Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanda Pharmaceuticals Inc filed Critical Vanda Pharmaceuticals Inc
Application granted granted Critical
Publication of FI3710000T3 publication Critical patent/FI3710000T3/fi

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
FIEP18821773.1T 2017-11-17 2018-11-16 Tradipitantti käytettäväksi gastropareesin hoidossa FI3710000T3 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762587681P 2017-11-17 2017-11-17
PCT/US2018/061593 WO2019099883A1 (en) 2017-11-17 2018-11-16 Method of treatment of gastrointestinal diseases with tradipitant

Publications (1)

Publication Number Publication Date
FI3710000T3 true FI3710000T3 (fi) 2025-07-03

Family

ID=64734107

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP18821773.1T FI3710000T3 (fi) 2017-11-17 2018-11-16 Tradipitantti käytettäväksi gastropareesin hoidossa

Country Status (19)

Country Link
US (4) US20200030307A1 (enExample)
EP (1) EP3710000B1 (enExample)
JP (1) JP7306614B2 (enExample)
KR (2) KR102864285B1 (enExample)
CN (2) CN119074729A (enExample)
AU (1) AU2018367623B2 (enExample)
BR (1) BR112020009520A2 (enExample)
CA (1) CA3081582A1 (enExample)
CL (1) CL2020001290A1 (enExample)
DK (1) DK3710000T3 (enExample)
ES (1) ES3032138T3 (enExample)
FI (1) FI3710000T3 (enExample)
HR (1) HRP20250615T1 (enExample)
HU (1) HUE071527T2 (enExample)
IL (1) IL274541B2 (enExample)
MX (1) MX2020005167A (enExample)
PT (1) PT3710000T (enExample)
SI (1) SI3710000T1 (enExample)
WO (1) WO2019099883A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016141341A1 (en) * 2015-03-04 2016-09-09 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant
US20210228555A1 (en) * 2018-06-08 2021-07-29 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant
US10821099B2 (en) 2018-09-28 2020-11-03 Vanda Pharmaceuticals Inc. Use of tradipitant in motion sickness
CN111918701B (zh) * 2018-09-28 2024-08-02 万达制药公司 曲地匹坦在晕动病中的用途
WO2020117811A1 (en) 2018-12-03 2020-06-11 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant
JP7791832B2 (ja) 2020-03-26 2025-12-24 バンダ・ファーマシューティカルズ・インコーポレイテッド トラジピタントによる下気道感染症の治療
WO2023019084A1 (en) 2021-08-12 2023-02-16 Vanda Pharmaceuticals Inc. Treatment of gastric accommodation with tradipitant
US20240350469A1 (en) 2021-08-31 2024-10-24 Vanda Pharmaceuticals Inc. Treatment of lower respiratory tract infection with tradipitant
JP2025542424A (ja) 2022-12-21 2025-12-25 バンダ・ファーマシューティカルズ・インコーポレイテッド トラジピタントによる処置の方法
EP4599831A1 (en) 2024-02-09 2025-08-13 Vanda Pharmaceuticals Inc. Treatment of gastroparesis with tradipitant

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003230829B8 (en) 2002-04-26 2008-12-11 Eli Lilly And Company Triazole derivatives as tachykinin receptor antagonists
KR100848407B1 (ko) * 2003-10-24 2008-07-28 일라이 릴리 앤드 캄파니 {2-[1-(3,5-비스-트리플루오로메틸벤질)-5-피리딘-4-일-1h-[1,2,3]트리아졸-4-일]-피리딘-3-일}-(2-클로로페닐)-메탄온의 신규 결정질 형태
WO2008079600A1 (en) * 2006-12-20 2008-07-03 Eli Lilly And Company Novel intermediate and process useful in the preparation of {2-[1-(3,5-bis-trifluoromethyl-benzyl)-5-pyridin-4-yl-1h-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone
HRP20140759T1 (hr) * 2009-11-18 2014-10-24 Helsinn Healthcare S.A. Kompozicije za lijeäśenje središnje posredovane muäśnine i povraä†anja
WO2016141341A1 (en) * 2015-03-04 2016-09-09 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant
CA3009325A1 (en) 2015-12-22 2017-06-29 Takeda Pharmaceutical Company Limited Tripartite modulators of endosomal g protein-coupled receptors

Also Published As

Publication number Publication date
JP2021503480A (ja) 2021-02-12
US20210330656A1 (en) 2021-10-28
AU2018367623A1 (en) 2020-05-21
US20200030307A1 (en) 2020-01-30
NZ764107A (en) 2024-07-05
EP3710000B1 (en) 2025-04-23
CN111343981A (zh) 2020-06-26
IL274541B1 (en) 2024-06-01
US20210093621A1 (en) 2021-04-01
SI3710000T1 (sl) 2025-07-31
KR20200088346A (ko) 2020-07-22
WO2019099883A1 (en) 2019-05-23
PT3710000T (pt) 2025-05-29
RU2020119259A (ru) 2021-12-17
AU2018367623B2 (en) 2024-03-28
CN119074729A (zh) 2024-12-06
CL2020001290A1 (es) 2020-11-13
KR102864285B1 (ko) 2025-09-24
IL274541B2 (en) 2024-10-01
EP3710000A1 (en) 2020-09-23
JP7306614B2 (ja) 2023-07-11
KR20250140655A (ko) 2025-09-25
BR112020009520A2 (pt) 2020-11-03
HUE071527T2 (hu) 2025-09-28
MX2020005167A (es) 2020-08-20
HRP20250615T1 (hr) 2025-07-18
US20230390269A1 (en) 2023-12-07
DK3710000T3 (da) 2025-06-16
ES3032138T3 (en) 2025-07-15
IL274541A (en) 2020-06-30
CA3081582A1 (en) 2019-05-23

Similar Documents

Publication Publication Date Title
FI3710000T3 (fi) Tradipitantti käytettäväksi gastropareesin hoidossa
JP2013511507A5 (enExample)
JP2006526644A5 (enExample)
JP2012533565A5 (enExample)
JP2021503480A5 (enExample)
ME02474B (me) Terapijski režimi
RU2016117186A (ru) Комбинированная композиция, содержащая тадалафил и амлодипин
JP2019529570A5 (enExample)
WO2007031887A3 (en) Extended release pharmaceutical composition of metformin and a process for producing it
JP2016505050A5 (enExample)
JP2011516544A5 (enExample)
CN103070865A (zh) 一种以琥珀酸普卡必利为活性成分的固体制剂及其应用
JP6864970B2 (ja) 胃腸薬組成物
JP2019099579A5 (enExample)
KR20110071096A (ko) 기능성 소화관 장해의 예방 및/또는 치료제
JP2017511350A5 (enExample)
JP2008056567A (ja) 胃腸疾患の治療又は予防のための医薬
CN102210681B (zh) 四氢嘧啶及其衍生物在制备治疗消化道疾病药物中的应用
WO2011108882A3 (ko) 유효성분으로서 레바미피드를 함유하는 골관절염 예방 또는 치료용 약학 조성물
IL300044A (en) N'-(2-chloro-6-methylbenzoyl)-4-methyl-3-[2-(3-quinolyl) ethynyl]-benzohydrazide for treatment of alzheimer's disease
TWI430807B (zh) 協同性地增高消化管運動賦活作用之胃腸藥組成物
JP6940265B2 (ja) 止瀉剤組成物
WO2020013776A3 (en) Synergistic effect of naproxen and a gastro protective agent for the treatment of pain and inflammation
WO2011100668A4 (en) Methods and compositions of civamide to treat diseases of the intestines
JP6878021B2 (ja) トリプタンとアスコルビン酸を含有する医薬組成物